Drugs / bizelesin
bizelesin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00003021 | Aug 1997 → Nov 2002 | cancer of unknown primary site | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bizelesin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003021 ↗ |
| Known as | Bizelesina | ChEMBL registry synonym — accepted as the source's own label CHEMBL284642 ↗ |
| Known as | Bizelesine | ChEMBL registry synonym — accepted as the source's own label CHEMBL284642 ↗ |
| Known as | NSC-615291 | ChEMBL registry synonym — accepted as the source's own label CHEMBL284642 ↗ |
| Known as | U 77779 | ChEMBL registry synonym — accepted as the source's own label CHEMBL284642 ↗ |
| Modality | Small molecule | — CHEMBL284642 ↗ |
| Route | Intravenous | “Patients receive bizelesin IV on day 1.” NCT00003021 ↗ |